Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic analysis of oesophageal carcinoma (EC) identifies recurrent mutations in histone methyltransferases as a distinctive subset.

Oncogene·2026
Same author

Prognostic Value of Liver Metastases and KRAS Mutations in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Third-Line Placebo-Controlled Trials From the ARCAD CRC Database.

Clinical colorectal cancer·2026
Same author

Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancer.

NPJ precision oncology·2026
Same author

Medical Treatment Options in Colorectal Cancer - Expanding the Evidence.

NEJM evidence·2026
Same author

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01.

Nature communications·2025

Related Experiment Video

Updated: Apr 12, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.2K

Optimizing systemic therapy selection in metastatic colorectal cancer.

Axel Grothey1

  • 1Presented by Axel Grothey, MD, Professor of Oncology, Mayo Clinic, Rochester, Minnesota.

Journal of the National Comprehensive Cancer Network : JNCCN
|May 22, 2015
PubMed
Summary

Effective treatments for metastatic colorectal cancer involve multiple therapy lines and extended anti-vascular endothelial growth factor use. Identifying RAS pathway mutations is crucial for selecting optimal first-line therapies like chemotherapy plus bevacizumab or EGFR antibodies in RAS wild-type patients.

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

1.0K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

6.1K

Related Experiment Videos

Last Updated: Apr 12, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.2K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

1.0K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

6.1K

Area of Science:

  • Oncology
  • Medical Oncology
  • Gastrointestinal Oncology

Background:

  • Metastatic colorectal cancer (mCRC) treatment involves a complex, multi-line approach over approximately 3 years.
  • Several effective therapeutic agents are available for mCRC management.
  • Optimizing treatment sequencing and agent selection is critical for patient outcomes.

Purpose of the Study:

  • To outline a strategic approach for managing metastatic colorectal cancer.
  • To emphasize the importance of utilizing all recommended agents and extending anti-vascular endothelial growth factor (anti-VEGF) therapy.
  • To highlight the significance of identifying RAS pathway mutations for treatment selection.

Main Methods:

  • Review of current treatment guidelines and clinical evidence for metastatic colorectal cancer.
  • Analysis of therapeutic strategies across different lines of therapy.
  • Focus on the role of anti-VEGF agents and RAS pathway mutation status.

Main Results:

  • Multiple effective agents can be integrated throughout the mCRC treatment continuum.
  • Extended duration of anti-VEGF treatment is recommended.
  • Identification of RAS pathway mutations is essential for personalized therapy selection.
  • For RAS wild-type patients, first-line therapy options include chemotherapy plus bevacizumab or an epidermal growth factor receptor (EGFR) antibody.

Conclusions:

  • A comprehensive, multi-line treatment strategy is vital for metastatic colorectal cancer.
  • Personalized treatment based on RAS pathway status, particularly in RAS wild-type patients, improves therapeutic efficacy.
  • Extended anti-VEGF therapy and careful selection of first-line agents are key components of optimal mCRC management.